NAD(P)H: Quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions

Cardiovascular Toxicology

Volumn 12, Issue 1, 2012, Pages 39-45

  Zhu, Hong ^a,b   Li, Yunbo ^a,b  

^a EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Cardiovascular diseases; Gene polymorphisms; Inflammation; Metabolic syndrome; NQO1; Oxidative stress

Indexed keywords

20S PROTEASOME; ALPHA TOCOPHEROL; HYDROQUINONE; MITOMYCIN C; PROTEASOME; PROTEIN P53; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SUPEROXIDE; UBIQUINONE; UNCLASSIFIED DRUG;

ALLELE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; DEVELOPMENTAL GENE; DNA POLYMORPHISM; DRUG ACTIVITY; ELECTROCHEMICAL ANALYSIS; GENE EXPRESSION; GENE FUNCTION; GENOTYPE; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; MOLECULAR RECOGNITION; NONHUMAN; NQO1 GENE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; LIPID METABOLISM; METABOLIC SYNDROME X; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATIVE STRESS; POLYMORPHISM, GENETIC;

ANIMALIA; MAMMALIA;

EID: 84858795006     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-011-9136-9     Document Type: Review

References (39)

1. Ernster, L., & Lindberg, O. (1958). Animal mitochondria. Annual Review of Physiology, 20, 13-42.
2. Jaiswal, A. K., Burnett, P., Adesnik, M., & McBride, O. W. (1990). Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry, 29, 1899-1906. (Pubitemid 20074738)
3. Jaiswal, A. K. (1994). Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J Biol Chem, 269, 14502-14508.
4. Zhao, Q., Yang, X. L., Holtzclaw, W. D., & Talalay, P. (1997). Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proceedings of the National Academy of Sciences of the United States of America, 94, 1669-1674. (Pubitemid 27113893)
5. Liao, S., & Williams-Ashman, H. G. (1961). Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide. Biochemical and Biophysical Research Communications, 4, 208-213.
6. Dinkova-Kostova, A. T., & Talalay, P. (2010). NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Archives of Biochemistry and Biophysics, 501, 116-123.
7. Ross, D. (2004). Quinone reductases multitasking in the metabolic world. Drug Metabolism Reviews, 36, 639-654.
8. Seow, H. A., Penketh, P. G., Belcourt, M. F., Tomasz, M., Rockwell, S., & Sartorelli, A. C. (2004). Nuclear overexpression of NAD(P)H:quinone oxidoreductase 1 in Chinese hamster ovary cells increases the cytotoxicity of mitomycin C under aerobic and hypoxic conditions. J Biol Chem, 279, 31606-31612. (Pubitemid 39037830)
9. Adikesavan, A. K., Barrios, R., & Jaiswal, A. K. (2007). In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity. Cancer Research, 67, 7966-7971. (Pubitemid 47395126)
10. Siegel, D., Gustafson, D. L., Dehn, D. L., Han, J. Y., Boonchoong, P., Berliner, L. J., et al. (2004). NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Molecular Pharmacology, 65, 1238-1247. (Pubitemid 38543494)
11. Zhu, H., Jia, Z., Mahaney, J. E., Ross, D., Misra, H. P., Trush, M. A., et al. (2007). The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger. Cardiovascular Toxicology, 7, 202-211. (Pubitemid 47575005)
12. Cao, Z., & Li, Y. (2004). The chemical inducibility of mouse cardiac antioxidants and phase 2 enzymes in vivo. Biochemical and Biophysical Research Communications, 317, 1080-1088. (Pubitemid 38496420)
13. Siegel, D., & Ross, D. (2000). Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radical Biology and Medicine, 29, 246-253.
14. Griendling, K. K., & FitzGerald, G. A. (2003). Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation, 108, 1912-1916. (Pubitemid 37296532)
15. Griendling, K. K., & FitzGerald, G. A. (2003). Oxidative stress and cardiovascular injury: Part II: Animal and human studies. Circulation, 108, 2034-2040. (Pubitemid 37337574)
16. Asher, G., Lotem, J., Cohen, B., Sachs, L., & Shaul, Y. (2001). Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proceedings of the National Academy of Sciences of the United States of America, 98, 1188-1193. (Pubitemid 32121208)
17. Anwar, A., Dehn, D., Siegel, D., Kepa, J. K., Tang, L. J., Pietenpol, J. A., et al. (2003). Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. Journal of Biological Chemistry, 278, 10368-10373. (Pubitemid 36800300)
18. Asher, G., Tsvetkov, P., Kahana, C., & Shaul, Y. (2005). A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes and Development, 19, 316-321. (Pubitemid 40189294)
19. Garate, M., Wong, R. P., Campos, E. I., Wang, Y., & Li, G. (2008). NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33(ING1b). EMBO Rep, 9, 576-581. (Pubitemid 351772922)
20. Alard, A., Fabre, B., Anesia, R., Marboeuf, C., Pierre, P., Susini, C., et al. (2010). NAD(P)H quinone-oxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome. Molecular and Cellular Biology, 30, 1097-1105.
21. Nioi, P., & Hayes, J. D. (2004). Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutation Research, 555, 149-171. (Pubitemid 39359178)
22. Chen, X. L., Varner, S. E., Rao, A. S., Grey, J. Y., Thomas, S., Cook, C. K., et al. (2003). Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism. Journal of Biological Chemistry, 278, 703-711. (Pubitemid 36790739)
23. Lee, S. O., Chang, Y. C., Whang, K., Kim, C. H., & Lee, I. S. (2007). Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells. Cardiovascular Research, 76, 331-339. (Pubitemid 350198593)
24. Kim, S. Y., Jeoung, N. H., Oh, C. J., Choi, Y. K., Lee, H. J., Kim, H. J., et al. (2009). Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circulation Research, 104, 842-850.
25. Hur, K. Y., Kim, S. H., Choi, M. A., Williams, D. R., Lee, Y. H., Kang, S. W., et al. (2010). Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway. Atherosclerosis, 211, 69-76.
26. Gaikwad, A., Long, D. J., 2nd, Stringer, J. L., & Jaiswal, A. K. (2001). In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. Journal of Biological Chemistry, 276, 22559-22564.
27. Hwang, J. H., Kim, D. W., Jo, E. J., Kim, Y. K., Jo, Y. S., Park, J. H., et al. (2009). Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes, 58, 965-974.
28. Pink, J. J., Planchon, S. M., Tagliarino, C., Varnes, M. E., Siegel, D., & Boothman, D. A. (2000). NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. Journal of Biological Chemistry, 275, 5416-5424. (Pubitemid 30115173)
29. Bey, E. A., Bentle, M. S., Reinicke, K. E., Dong, Y., Yang, C. R., Girard, L., et al. (2007). An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proceedings of the National Academy of Sciences of the United States of America, 104, 11832-11837. (Pubitemid 47175098)
30. Kelsey, K. T., Ross, D., Traver, R. D., Christiani, D. C., Zuo, Z. F., Spitz, M. R., et al. (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. British Journal of Cancer, 76, 852-854. (Pubitemid 27401934)
31. Gaedigk, A., Tyndale, R. F., Jurima-Romet, M., Sellers, E. M., Grant, D. M., & Leeder, J. S. (1998). NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics, 8, 305-313. (Pubitemid 28372324)
32. Traver, R. D., Siegel, D., Beall, H. D., Phillips, R. M., Gibson, N. W., Franklin, W. A., et al. (1997). Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). British Journal of Cancer, 75, 69-75. (Pubitemid 27007275)
33. Han, S. J., Kang, E. S., Kim, H. J., Kim, S. H., Chun, S. W., Ahn, C. W., et al. (2009). The C609T variant of NQO1 is associated with carotid artery plaques in patients with type 2 diabetes. Molecular Genetics and Metabolism, 97, 85-90.
34. Isbir, C. S., Ergen, A., Tekeli, A., Zeybek, U., Gormus, U., & Arsan, S. (2008). The effect of NQO1 polymorphism on the inflammatory response in cardiopulmonary bypass. Cell Biochemistry and Function, 26, 534-538. (Pubitemid 351947706)
35. Martin, N. J., Collier, A. C., Bowen, L. D., Pritsos, K. L., Goodrich, G. G., Arger, K., et al. (2009). Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. Mutation Research, 674, 93-100.
36. Shyu, H. Y., Fong, C. S., Fu, Y. P., Shieh, J. C., Yin, J. H., Chang, C. Y., et al. (2010). Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke. Clinical Chemistry of Acta, 411, 840-845.
37. Palming, J., Sjoholm, K., Jernas, M., Lystig, T. C., Gummesson, A., Romeo, S., et al. (2007). The expression of NAD(P)H:quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction. Journal of Clinical Endocrinology and Metabolism, 92, 2346-2352. (Pubitemid 46997144)
38. Wang, G., Zhang, L., & Li, Q. (2006). Genetic polymorphisms of GSTT1, GSTM1, and NQO1 genes and diabetes mellitus risk in Chinese population. Biochemical and Biophysical Research Communications, 341, 310-313. (Pubitemid 43152107)
39. Kristiansen, O. P., Larsen, Z. M., Johannesen, J., Nerup, J., Mandrup-Poulsen, T., & Pociot, F. (1999). No linkage of P187S polymorphism in NAD(P)H: quinone oxidoreductase (NQO1/ DIA4) and type 1 diabetes in the Danish population. DIEGG and DSGD. Danish IDDM epidemiology and genetics group and the Danish study group of diabetes in childhood. Human Mutation, 14, 67-70.